Rivard G E, Aledort L
Department of Pediatrics, University of Montreal, Quebec, Canada.
Haemophilia. 2008 Mar;14(2):271-5. doi: 10.1111/j.1365-2516.2007.01616.x. Epub 2008 Jan 8.
The adequacy of perioperative haemostasis with a high-purity, plasma-derived factor VIII product containing von Willebrand factor was retrospectively evaluated in 39 patients with type 1, 2 or 3 von Willebrand disease who underwent 61 major or minor surgical or invasive procedures. Overall, 93.5% of the responses to treatment were rated as excellent or good by the physician investigators. These ratings were confirmed by an independent panel of physician referees.
对39例1型、2型或3型血管性血友病患者进行了回顾性评估,这些患者接受了61次大手术或小手术或侵入性操作,使用了含血管性血友病因子的高纯度血浆源性凝血因子VIII产品来评估围手术期止血的充分性。总体而言,医师研究者将93.5%的治疗反应评为优秀或良好。这些评级得到了独立医师评审小组的确认。